IC
FLNA

Intersect Capital’s Filana Therapeutics FLNA Stock Holding History

Intersect Capital’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,252
Closed -$192K – 415
2021
Q2 		$192K Buy
+2,252
New +$121K 0.03% 360
2021
Q1 		– Sell
-20,000
Closed -$136K – 339
2020
Q4 		$136K Hold
20,000
– – 0.03% 282
2020
Q3 		$230K Buy
+20,000
New +$90.2K 0.06% 206

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Intersect Capital's FLNA Position: Q3 2021 in Review

Intersect Capital sold out of Filana Therapeutics (FLNA) in Q3 2021, closing a stake of 2,252 shares — an estimated $192K sold.

Intersect Capital first reported a position in FLNA in Q3 2020 and held it in 3 quarters. The position peaked at $230K in Q3 2020. 180 funds tracked by Wall St. Rank hold FLNA as of Q3 2021.

  • Intersect Capital reported no remaining Filana Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Intersect Capital sold 2,252 Filana Therapeutics shares in Q3 2021, an estimated $192K.
  • Intersect Capital first reported a position in Filana Therapeutics in Q3 2020 and held it in 3 quarters.
  • Intersect Capital's Filana Therapeutics position peaked at $230K in Q3 2020.
  • 180 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2021.

Based on Intersect Capital's 13F filing for Q3 2021, filed 15 Oct 2021.